S.Compound
S. Compound is a
proprietary herbal formulation based on Sallaki (Boswellia Serrata), a
non-steroidal, anti-arthritic, and 100% herbal formulation. It is totally free
from chemicals, synthetics and heavy metals (even as excipients), and is wholly
safe and non-toxic in nature. S. Compound is a new class of disease modifying
formulation, with a novel mode of action. Developed after several years of
research, the main constituent of this pure plant product is Salai Guggul (Boswellia
Serrata). Historically, this product is mentioned in Sushruta Samhita Sutra
Sthanam 4, an ancient Ayurvedic text.
SPECIFICATIONS: S.COMPOUND (BOSWELLIA
SERRATA)
COMPOSITION: S. Compound (Boswellia
Serrata) processed in herbal extracts (Rasnadi & Suranjan) 300 mg.
CHEMICAL COMPOSITION: Boswellic
acids are a complex mixture of Pentacyclic Triterpenic acids:
β-boswellic acids
Acetyl-β-boswellic acid
I I-Keto-β-boswellic acids
Acetyl-I I-Keto-β-boswellic acids. |
Efficaciousness proved in Controlled Studies
Controlled Studies at the Government Ayurvedic
College Hospital and Government Medical College (both in Jammu), were conducted,
established its efficacy in the treatment of Rheumatoid Arthritis and Osteo
Arthritis.
Meeting International Standards
S. Compound is manufactured by Rahul Pharma at its
state-of-the-art, GMP Certified facilities at Jammu.
All raw materials, including gelatin capsules and
plastic containers used in the processing to the finished product, are sourced
from reputed, GMP certified companies or directly from the forest area under the
supervision of experts.
Gum is purified and then processed in the
ingredients of Raasnadi (a classical Ayurvedic composition based on medicinal
plants mentioned in Ayurvedic Texts/Suranjan).
Manufacturing / Processing Formulations under
advisory consultancy from Regional Research Laboratory, Jammu, a unit of Counil
of Scientific & Industrial Research (CSIR), Government of India.
Pharmacology
A conventional, non-steroidal, anti-inflammatory
agent, the action of S. Compound is mediated through the vascular phenomenon. It
improves the blood supply to the joints and restores integrity of vessels
obliterated by the spasm of internal damage. It exerts its action through
inhibition of lipoxygenase enzyme, on the formation of Leukotreine LTB4, a novel
mode of action till now. Unlike other non-steroidal anti-inflammatory drugs,
S.Compound has beneficial and therapeutic effects. It has been found to be free
from pre-clinical acute and chronic toxicity. Clinical studies at Government
Medical College and Regional Research Laboratory, Jammu have established it to
be a safe anti-arthritic and anti-asthmatic drug.
Toxicology
Chronic Toxicity in rabits for three months: Salai
Guggul in 2% gum acacia in two doses and one control of 2% gum acacia were
administered orally in three groups of rabits. Hematological and biochemical
estimation revealed no deviation from normal parameters. Macroscopic and
microscopic examination of vital organs revealed no change in weight, size,
coloration and histo-pathology. Chronic toxicity in monkeys also showed no
change in hematological and biochemical parameters.
|
|
CERTIFIED BY
Government of India
In 1985, the Advisor Ayurveda, Ministry of Health
& Family Welfare, Government of India, sought information about S. Compound, and
a test report from Central Drug Research Institute (CDRI), Lucknow, was
obtained. After clinical studies, CDRI established is better activity as
compared to Phenylbutazone, a drug withdrawn from a number of countries due to
its toxic effects.
Post Graduate Department of Medicine, Government
Medical College, Jammu
Further work on Osteo Arthritis taken up by the
Post Graduate Department of Medicine, Government Medical College, Jammu, also
confirmed S. Compound's efficacy in its treatment. The research work was
published in Indian Practitioner.
Directorate of Indian System of Medicine, Jammu &
Kashmir
After the creation of Directorate of Indian System
of Medicines in J&K state in 1988, it took up trials of S. Compound and
certified its efficacy. The formulation was tested by Ayurvedic experts on
thousands of patients in more than 400 dispensaries.
Department of Pharmaceutical Sciences, Tubingen
University, Germany
The Department of Pharmaceutical Sciences,
Tubingen University, Germany, has established S. Compound as a Leukotreine
Inhibitor, and that it has efficacy in all inflammatory conditions.
Published Research Work in International Journals
Research work on S. Compound has been published in
international medical journals such as Planta Medica and the European Journal of
Medical Research.
Efficaciousness proved in Controlled Studies
Controlled Studies at the Government Ayurvedic
College Hospital and Government Medical College (both in Jammu), were conducted,
established its efficacy in the treatment of Rheumatoid arthritis and Osteo
Arthritis.
National and International Accolades for S.
Compound
Hope for Arthritis patients
New Delhi, June 21 (UNI)
It was observed during trials conducted in
patients suffering from Chronic Rheumatoid Arthritis that the formulation
afforded between 70-80% relief with regard to swelling in joints and tenderness,
morning stiffness, walking time and patients own impressions of overall disease
activity. According to Eastern Pharmacist, a leading Pharmaceutical journal, it
appears that the formulation acts on the basic pathological process responsible
for the genesis of Rheumatoid Arthritis.
Courtesy: Hindustan Times, Times of India,
National Herald, The Statesman, The Tribune, June 22, 1982
S. Compound: A traditional drug for Osteo
Arthritis
The Indian Practitioner: January 1993
S. Compound was tried on 30 patients of chronic
Osteo Arthritis of primary aetiology. While 60% of the patients started showing
improvement in symptoms by the second week, and by twelve weeks had full relief,
33.3% of the patients had o take the formulation for twenty four weeks for full
relief. In the control group treated with Ibuprofen, only 30% showed
improvement. Very few side effects were noted in the patients treated with S.
Compound as compared to patients treated with Ibuprofen.
The study was carried out by Deptt. of Post
Graduate Medicine, Government Medical College, Jammu.
S. Compound has benefited thousands of patients of
crippling disorders
Dr Hardyal Singh, M.D., MNAMS, Director-Principal,
Guru Ram Dass Institute of Medical Sciences & Research, Amritsar.
Health Minister's Statement in Indian Parliament
November, 1983
"Rahul Pharma, Jammu, has developed an Ayurvedic
formulation named S. Compound. The main ingredient of the drug is Salai Guggul.
This is claimed to be very effective for the treatment of Rheumatoid Arthritis."
Central Drug Research Institute, Lucknow
December 1984
"S. Compound has better activity than
Phenylbutazone."
Studies with S. Compound in the treatment of
Rheumatoid arthritis
Dr. Shayma Wanchoo, Assistant Director, Health
Services, J&K Government and Dr. Gurmeet Singh, Medical Officer, Government
Ayurvedic Dispensary, Jammu
The study was conducted on twenty patients ailing
from Rheumatoid Arthritis and showing major symptoms like pain, swelling,
stiffness, effusion of the joints and restriction of movement. They had marked
morning stiffness.
Patients treated with S. Compound indicated
excellent recovery during the course of treatment. Though progress varied in
different patients, it was noticed that there was 75-85% relief with regard to
morning stiffness, pain and swelling of the joints, walking time and the
patients own impressions of overall disease activity.
It was observed that the noteworthy effect of S.
Compound was due to its anti inflammatory, analgesic, anti arthritic action and
also due to the prevention of degenerative changes. The most significant factor
is that none of the patients was exposed to after effects during the treatment
conducted with S. Compound.
Souvenir, All India Ayurvedic Meet, November
1983.
A ray of hope for Arthritis
Daily News, Colombo, Sri Lanka
There is heartening news for all those suffering
from Rheumatic and other skeletal disorders. Thanks to Ayurvedic S. Compound, a
herbal medicine developed by Dr. Virender Mahajan, illustrious son of late Dr.
Som Nath Gupta Vaidya Vachaspati, an eminent Ayurvedic Physician hailing from
Mirpur.
According to Dr. Mahajan, Director, Maharishi
Charak Ayurvedic Centre for Rheumatic Diseases, S. Compound provides quick
relief from pain, inflammation and tenderness without causing any side effects
as in the case of Phenylbutazone, Ibuprofen and other synthetic medicines. |
Rheumatic specialist declared Man
of the Year
The Kashmir Times, Jammu, January 20,
2003
Kashmir Times News Service, January
19
American Biographical Institute Inc.,
North Carolina, USA, publishers of Biographical Reference works since
1967, has declared Dr. Virender Mahajan, Medical Director, Maharishi
Charak Ayurvedic Centre for Rheumatic Diseases, Jammu, as the Man of the
Year 2003.
A communication sent by its President
J.M. Evans stated," I am delighted to announce your nomination for the
prestigious title 'Man of the year 2003'. The Institute's International
Board of Research decided on your nomination due to your overall
accomplishments and contribution to the society." |
REFERENCES |
Indian Journal of Pharmacology 12:1:P59:1980 |
Eastern Pharmacist
XXV:P293:1982 |
British Pharmaco Congress UK April: 1981 C 49 |
All Indian Meet Souvenir Nov:1983 |
Sushruta Samhita S.S 38 |
The Indian Practitioner:XLVI : I:P 69:1993 |
Ind.Drugs,24:221(1987) |
Ind.J.Pharmacol:16:115,1984 |
Dravayagunavignyana, Continental Prakashan, Pune(1982) |
Effects of Boswellia serrata
gum resin in Patients with bronchial asthma: result of a double
blind,placebo-controlled, 6-week clinical study. |
Eur
J Med Res.1998 Nov 17;3(11):5 1 1-4 |
Effects of gum resin of
Boswellia in Patients with chronic colitis. |
Planta
Med. 2001 Jul;67(5):391-5 |
Clastagenic
effects of dietary supplement--Spirulina alga, and some medical
plant products from Boswellia serrata, Withania somnifera on
mice. Indian J Exp Biol.2001 oct:39(10):1068-70 |
High-performance thin layer
chromatographic analysis of anti-inflammatory triterpenoids from
Boswellia serrata Roxb. |
PhytochemAnal.2001
Nov-Dec:12(6):374-6 |
Boswellic
acids activate p42(MAPK) and p38 MAPK and stimulate Ca(2+)
mobilization. |
Biochem
Biophys Res Commun.002 Jan 11;290(1):185-90 |
A reversed phase high
performance liquid chromatography method for the analysis of
boswellia acid in Boswellia serrata. |
Planta
Med. 2001 Nov;67(8):778-80 |
Sitmulation
of leukotriene synthesis in intact polymorphonuclear cells by
the 5-lipoxygenase inhibitor 3-oxo-tirucallic acid. |
Mol Pharmacol 2001
Aug;60(2):67-73 |
Acetyl-11-Keto-beta-boswellic
acid, a constituent of a herbal medicine from Boswellic serrata
resin, attenuates experimental ileitis. |
Int
J Colorectal Dis.2001 Apr: 16(2):88-95 |
Treatement
of osteoarthritis with a herbomineral formulaion: a double-blind,placebo-controlled,cross-over
study. |
J Ethnopharmacol. 1991
May-June:33(1-2):91- |
Mechanism of
anti-carcinogenic activities of curcumineBoswellic acids. |
J Ethnopharmacol. 1993 Mar:
38(2-3):113-9 |
Anti-tumor and
anti-carcinogenic activities of triterpenoid, beta-Boswellic
acid. Biofactors.2000;13(1-4):225-30 |
Inhibition of leukotriene B4
formation in rat peritoneal neutrophils by an ethanolic extract
of the gum resin exudate of Boswellia serrata. |
Planta
Med. 1991,Jun;57(3):203-7 |
Therapy of active Crohn
disease with Boswellia serrata extract H 15] |
Z Gastroenterol.2001
Jan:39(1):11-7, German |
The etiologies,
Pathophysiology, and alternative/ complementary treatement of
Asthma. |
Altern
Med Rev.2001 Feb;6(1):20:47 |
Salai
Guggal-Boswellia serrata: from a herbal medicine to a non-redox
inhibitor of leukotriene biosynthesis. |
Eur
J Med Res.1996 May 24:1(8):369-70 |
Effects of Boswellia acid
extracted from a herbal medicine on the biosynthesis of
leukotrienes and the course of experimental autoimmune
encephalomyelitis |
Arzneimittelforschung.1998
Jun:48(6):668-74 |
Inhibitory activity of
boswellic acid from Boswellia serrata against human leukemia
HL-60 cells in culture. |
Planta
Med. 1998 May;64(4):328-31 |
Effects of Boswellia serrata
gum resin in Patients with Ulcerative colitis. EJ Med Res
1997jan::37-43 |
|